Full-Time

Quality Control Senior Analyst

Raw Materials

Confirmed live in the last 24 hours

Beam Therapeutics

Beam Therapeutics

501-1,000 employees

Develops precision genetic medicines using base editing

Biotechnology
Healthcare

Mid, Senior

Durham, NC, USA

Must work onsite 5 days a week.

Category
Lab & Research
Life Sciences
Requirements
  • BS in a scientific discipline with at least 4 years' experience in pharmaceutical/biotech industry
  • Experience with raw material testing programs and quality control methodologies
  • Experience with interpreting and applying compendial test monographs
  • Ability to communicate and work independently with scientific/technical personnel
  • Must be able to work onsite 5 days a week
  • Strong knowledge of GMPs, SOPs, and Quality system processes
  • Excellent organizational skills
Responsibilities
  • Perform QC sampling, testing and release of incoming raw materials, reagents, and components
  • Support onboarding and qualification of materials and components by creating risk assessments and material specifications
  • Interface with cross-functional stakeholders, including Supply Chain, Manufacturing, Manufacturing Science & Technologies, Process Development and Analytical Development
  • Performs routine maintenance of lab equipment as applicable
  • Own and/or support laboratory deviations, OOS investigations, CAPA, change control
  • Maintains strict adherence to cGMP compliance and all applicable regulations
  • Supports regulatory inspections, external client and internal audits as required.
Desired Qualifications
  • Experience in cell and gene therapy manufacturing environment a plus
  • Experience performing laboratory investigations, including out of specification investigations

Beam Therapeutics develops precision genetic medicines using a technique called base editing, which allows for precise modifications to the genetic code to potentially correct mutations that lead to serious diseases. Their primary focus is on treating genetic disorders, such as sickle cell disease, with the aim of providing lifelong cures rather than temporary solutions. The company invests significantly in research and development to create new therapies and generates revenue through partnerships, licensing agreements, and future commercialization of their treatments. Beam Therapeutics distinguishes itself from competitors by its commitment to rigorous scientific research and a talented team of experts dedicated to advancing genetic medicine. The ultimate goal of the company is to deliver lasting cures for patients suffering from genetic conditions.

Company Stage

IPO

Total Funding

$215.9M

Headquarters

Cambridge, Massachusetts

Founded

2017

Growth & Insights
Headcount

6 month growth

0%

1 year growth

-1%

2 year growth

0%
Simplify Jobs

Simplify's Take

What believers are saying

  • Base editing technology is gaining traction as a precise genetic correction method.
  • The $250 million deal with Eli Lilly boosts Beam's financial and strategic position.
  • Christi Shaw's appointment to the board brings valuable biotech leadership.

What critics are saying

  • Competition from CRISPR Therapeutics could impact Beam's market share.
  • Recent restructuring and layoffs may lead to operational challenges.
  • New CFO transition might pose financial management challenges.

What makes Beam Therapeutics unique

  • Beam Therapeutics uses base editing, a precise genetic correction method.
  • The company focuses on lifelong cures for genetic disorders like sickle cell disease.
  • Beam's strategic partnerships, like with Eli Lilly, enhance its market position.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Flexible Work Hours